Inhibikase Therapeutics, Inc. Common Stock (IKT) Ownership & Trading Activity
Institutional holders, insider transactions, and congressional trades for IKT. 13F holdings as of 2026-06-30.
In 13F filings for the quarter ended June 30, 2026, 103 institutions reported holding IKT, with 117.9 million shares worth $239.2 million in aggregate.
Top Institutional Holders
| Institution | Shares | Value | Change |
|---|---|---|---|
| Sands Capital Ventures | 13,018,965 | $26M | UNCHANGED |
| Soleus Capital Management | 10,875,000 | $22M | UNCHANGED |
| Trails Edge Capital Partners | 9,051,318 | $18M | INCREASED |
| Fairmount Funds Management | 8,625,000 | $18M | UNCHANGED |
| BlackRock | 7,768,057 | $16M | INCREASED |
Full institutional holdings, insider history, and congressional trades for Inhibikase Therapeutics, Inc. Common Stock on SentiSense.